Researchers at the Icahn School of Medicine at Mount Sinai have discovered how genetics can affect the success of venetoclax, ...

Tyler Sandahl, PharmD, of Mayo Clinic, and Michael Byrne, DO, of Tennessee Oncology, discuss practical advice for bringing ...

Johnson & Johnson (J&J) has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies ...

a type of white blood cell in the body, may predict whether people who have relapsed multiple myeloma are going to respond well to CAR-T ... Sep. 29, 2023 — Patients with multiple myeloma ...

Biotech HaemaLogiX – which counts former health minister Greg Hunt as a director – is preparing a 2025 ASX listing, as it ...

Researchers at the Icahn School of Medicine at Mount Sinai have discovered how genetics can affect the success of venetoclax, ...

The key secondary end point of overall survival was met in the DREAMM-7 trial of belantamab mafodotin for the treatment of patients with relapsed/refractory multiple myeloma. Sham Mailankody, MBBS, ...

William Blair analyst Matt Phipps has estimated that there are around 3,000 multiple myeloma patients in the ... company's heritage of innovation in blood cancers and transform patients' lives ...

Am J Health Syst Pharm. 2007;64(17):1799-1807. Despite a similar chemical structure to thalidomide, the toxicity profile of lenalidomide has been shown to be quite different. The major dose ...

You will be able to get a quick price and instant permission to reuse the content in many different ways. The humerus is a common site for metastatic bone disease and the common primaries include ...

Since birth, identical twins Karen and Linda have been inseparable. They said they would do anything for each other, so when ...

Experience convenient blood cancer treatment close to home. Find out how this unique partnership brings autologous stem cell ...